Synthetic ventures into the furanocembranes: bielschowskysin and beyond by Lear, Martin
Synthetic Ventures into the Furanocembranes: Bielschowskysin and Beyond 
Martin J. Lear 
Joseph Banks Laboratories, School of Chemistry, Brayford Pool, Lincoln, LN6 7TS, United Kingdom  
MLear@lincoln.ac.uk  
Natural products often unite chemical structure and 
biological function in unforeseen ways. Such facets 
have long driven targeted synthesis and drug campaigns. 
The concerted challenge for the organic chemist is not 
only to orchestrate a sequence of synthetic methods into 
a workable, clever strategy, but also to advance and 
develop methods and tactics in conceptually new ways. 
The cembrane natural products hold such promise in 
both biological and chemical senses. They are a diverse 
class of macrocyclic diterpenes found in both plants and 
animals.[1] In particular, the furanocembranoids are 
highly oxidized cembranes, which have been discovered 
to exist in significant abundance and structural 
complexity, particularly in the Pseudopterogorgia sea 
whips from the Carribean, as well as from corals of the 
genus Sinularia, Plumarella, and Leptogorgia.[1c] 
Beyond their presumed antifeedant role in marine coral 
reefs, these biosynthetically-linked secondary 
metabolites display a wide range of biological activities; 
for example, derivatives and extracts of the 
pseudopterosins are not only being used medically as 
anti-inflammatory and analgesic agents, but are also 
being investigated as antimicrobial (TB, malaria) and as 
antitumour agents. 
Bielschowskysin (1) belongs to this diverse class of 
cembranoid diterpenes.[1b] In 2006, the Rodríguez group 
characterized 1 to be a tricyclo[9.3.0.02,10]tetradecane 
derived from the self-closure of a regular 
furanocembrane macro-skeleton (about the C6/C12 and 
C7/C11 carbon-carbon bonds).[2] Amid several 
strategies from other groups, we have been striving to 
develop [2+2]-transannulation tactics to construct the 
multicyclic skeleton of 1 via macrocyclic allenes like 2 
(Figure 1).[3] Previously, we secured the tricyclic 
cyclobutane core (C5-to-C12) of 1 by employing a 
stereocontrolled photochemical [2+2] cyclization of an 
allene-tethered -butenolide[3a] and have recently gained 
conformational insights into forming macrocyclic 
alkyne precursors to 2.[3b] 
In this talk, we summarise our progress to this 
family of natural products.[3c] In particular, we cover our 
macrocyclisation and transannulation strategies to the 
bielschowskyane framework (cf. 1). 
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